Mechanisms of Resistance to Radiation

  • Serra Kamer
  • Beste Melek Atasoy


Radiotherapy is a very effective treatment for achieving local tumor control in breast cancer. However, intrinsic tumor cell radioresistance is a significant clinical problem that limits the results of the treatment. Chemotherapeutics that could specifically sensitize tumors to radiation would greatly increase the ability to deliver higher doses while limiting radiation damage to surrounding normal tissue, but efforts to develop clinically useful tumor radiosensitizers have had limited success.


Breast Cancer Vascular Endothelial Growth Factor Epidermal Growth Factor Receptor Cancer Stem Cell Ataxia Telangiectasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hall EJ. Radiobiology for the radiologist. 5th ed. New York: Lippincott Williams & Wilkins; 2000.Google Scholar
  2. 2.
    Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRefGoogle Scholar
  3. 3.
    Helleday T, Lo J, van Gent DC, et al. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst). 2007;6:923–35.CrossRefGoogle Scholar
  4. 4.
    van Gent DC, van der Burg M. Non-homologous end-joining, a sticky affair. Oncogene. 2007;26:7731–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Jorgensen TJ. Enhancing radiosensitivity. Cancer Biol Ther. 2000;8(8):665–70.Google Scholar
  6. 6.
    Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA doublestrand breaks by non-homologous end-joining. Biochem J. 2009;417:639–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Hakem R. DNA-damage repair; the good, the bad and the ugly. EMBO J. 2008;27:589–605.PubMedCrossRefGoogle Scholar
  8. 8.
    Liang K, Jin W, Knuefermann C, Schmidt M, et al. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther. 2003;2(4):353–60.PubMedGoogle Scholar
  9. 9.
    Wollman R, Yahalom J, Maxy R, et al. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol. 1994;30:91–8.CrossRefGoogle Scholar
  10. 10.
    Zhou H, Kim YS, Peletier A, et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys. 2004;58:344–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Sambade MJ, Kimple RJ, Camp JT, et al. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. Int J Radiat Oncol Biol Phys. 2010;77(2):575–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997;57(15):3079–83.PubMedGoogle Scholar
  13. 13.
    Bartucci M, Morelli C, Mauro L, et al. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 2001;61:6747–54.PubMedGoogle Scholar
  14. 14.
    Iwamoto KS, Barber CL. Radiation-induced posttranscriptional control of M6P/IGF2r expression in breast cancer cell lines. Mol Carcinog. 2007;46(7):497–502.PubMedCrossRefGoogle Scholar
  15. 15.
    Manders P, Sweep FC, Tjan-Heijnen VC, et al. Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in nodenegative breast cancer patients. Clin Cancer Res. 2003;9:6363–70.PubMedGoogle Scholar
  16. 16.
    Linderholm B, Tavelin B, Grankvist K, et al. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer. 1999;81:727–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Labidi SI, Bachelot T, Ray-Coquard I, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer. 2009;9(2):118–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Abbott DW, Thompson ME, Robinson-Benion C, et al. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem. 1999;274:18808–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Baeyens A, Thierens H, Claes K, et al. Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. Int J Radiat Biol. 2004;80(10):745–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Nieuwenhuis B, Van Assen-Bolt AJ, Van Waarde-Verhagen MA, et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol. 2002;78(4):285–95.PubMedCrossRefGoogle Scholar
  21. 21.
    Coleman CN. Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2. Acta Oncol. 1999;38 Suppl 13:55–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Ernestos B, Nikolaos P, Koulis G, et al. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay. Int J Radiat Oncol Biol Phys. 2010;76(4):1199–205.PubMedCrossRefGoogle Scholar
  23. 23.
    Marchetti P, Cannita K, Ricevuto E, et al. Prognostic value of p53 molecular status in high-risk primary breast cancer. Ann Oncol. 2003;14(5):704–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Mayer C, Popanda O, Greve B, et al. A radiation-induced gene expression signature as a tool to predict acute radiotherapy induced adverse side effects. Cancer Lett. 2011;302(1):20–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Slijepcevic P. Is there a link between telomere maintenance and radiosensitivity? Radiat Res. 2004;161(1):82–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Zhong YH, Liao ZK, Zhou FX, et al. Telomere length inversely correlates with radiosensitivity in human carcinoma cells with the same tissue background. Biochem Biophys Res Commun. 2008;367(1):84–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Iwasaki T, Robertson N, Tsigani T, et al. Lymphocyte telomere length correlates with in vitro radiosensitivity in breast cancer cases but is not predictive of acute normal tissue reactions to radiotherapy. Int J Radiat Biol. 2008;84(4):277–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Barwell J, Pangon L, Georgiou A, et al. Is telomere length in peripheral blood lymphocytes correlated with cancer susceptibility or radiosensitivity? Br J Cancer. 2007;97(12):1696–700.PubMedCrossRefGoogle Scholar
  29. 29.
    Al-Ejeh F, Smart CE, Morrison BJ, et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis. 2011;32(5):650–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Lindeman GJ, Visvader JE. Insights into the cell of origin in breast cancer and breast cancer stem cells. Asia Pac J Clin Oncol. 2010;6:89–97.PubMedCrossRefGoogle Scholar
  31. 31.
    Phillips TM, Mc Bride WH, Pajonk F. The response of CD24(_/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98:1777–85.PubMedCrossRefGoogle Scholar
  32. 32.
    Woodward WA, Chen MS, Behbod F, et al. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA. 2007;104:618–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Han JS, Crowe DL. Tumor initiating cancer stem cells from human breast cancer cell lines. Int J Oncol. 2009;34:1449–53.PubMedGoogle Scholar
  35. 35.
    Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.PubMedCrossRefGoogle Scholar
  36. 36.
    Karimi-Busheri F, Rasouli NA, Mackey JY, et al. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res. 2010;12:R31.PubMedCrossRefGoogle Scholar
  37. 37.
    Harper LJ, Costena D, Gammon L, et al. Normal and malignant epithelial cells with stemlike properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer. 2010;10(166):2010.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Radiation OncologyEge UniversityBornovaTurkey
  2. 2.Department of Radiation OncologyMarmara UniversityPendikTurkey

Personalised recommendations